Real-World Epidemiology of Inflammatory Bowel Disease in Italy: Treatment Patterns, Adherence, and Costs in Patients with Ulcerative Colitis Treated with Mesalazine - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Real-World Inflammatory Bowel Disease in Italy: Mesalazine Treatment, Adherence, and Healthcare Costs in Ulcerative Colitis

  • By

  • Luca Degli Esposti

  • Chiara Veronesi

  • Silvia Calabria

  • Lisa Giannessi

  • Antonietta Barbieri

  • Fausto Bartolini

  • Stefania Dell’Orco

  • Fulvio Ferrante

  • Stefano Grego

  • Cataldo Procacci

  • Cristina Bezzio

  • Alessandro Armuzzi

  • October 12, 2026

Share

  • 1

    The retrospective study used linked administrative data from six Italian Local Health Units covering approximately 4 million residents.

  • 2

    The analysis reported contemporary national estimates of ulcerative colitis and Crohn’s disease incidence and prevalence in Italy.

  • 3

    Among patients with ulcerative colitis newly initiating mesalazine, treatment adherence during follow-up was suboptimal.

  • 4

    The study characterized demographics, comorbidities, treatment patterns, mesalazine adherence, and direct SSN healthcare expenditures in mesalazine-naive patients with ulcerative colitis.

  • 5

    Healthcare expenditures remained substantial and were largely attributable to hospitalizations.

Original Source(s)

Real-World Epidemiology of Inflammatory Bowel Disease in Italy: Treatment Patterns, Adherence, and Costs in Patients with Ulcerative Colitis Treated with Mesalazine

  • by Luca Degli Esposti, Chiara Veronesi, Silvia Calabria, Lisa Giannessi, Antonietta Barbieri, Fausto Bartolini, Stefania Dell’Orco, Fulvio Ferrante, Stefano Grego, Cataldo Procacci, Cristina Bezzio, Alessandro Armuzzi

  • October 12, 2026

Related Content

Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • September 30, 2026

  • 1 min
When Patients Have No Ride Home: Addressing Transportation Barriers That Exacerbate Disparities in Access to Timely Diagnostic Colonoscopies

A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

  • by

  • September 24, 2026

  • 11 min